“…Disease control (DC) (complete, partial response, and stable disease) was 80% at 11-month follow-up. Zhiwei Zhou, 1 Jianming Xu, 2 Lin Shen, 3 Jie Li, 3 Chunmei Bai, 4 Yihebali Chi, 5 Zhiping Li, 6 Nong Xu, 7 Ru Jia, 2 Enxiao Li, 8 Tianshu Liu, 9 Yuxian Bai, 10 Ying Yuan, 11 Xingya Li, 12 Xiuwen Wang, 13 Jia Chen, 14 Wei Wang, 1 Sha Guan, 15 Songhua Fan, 15 Weiguo Su. 15 7 The First Affiliated Hospital of Zhejiang University, Hangzhou, China; 8 The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; 9 Zhongshan Hospital of Fudan University, Shanghai, China; 10 Harbin Medical University Cancer Hospital, Harbin, China; 11 The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; 12 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 13 Qilu Hospital of Shandong University, Jinan, China; 14 Jiangsu Cancer Hospital, Nanjing, China; 15 Hutchison MediPharma Limited, Shanghai, China.…”